Trial NCT05020665

View at ClinicalTrials.gov 
Org. Study IDs: KB-ENTO-3001
Secondary IDs: 2021-000761-33

Last trial update was posted on 2024-01-10

MeSH Interventions

Cytarabine

MeSH Conditions

Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute

Other Conditions

Nucleophosmin 1-mutated Acute Myeloid Leukemia

Stopping Reasons

Termination was due to significant challenges associated with study enrollment in a genetic subset of fit participants in the front-line acute myeloid leukemia (AML) setting and other challenges associated with post-COVID impacts.

Limitations And Caveats

Early termination was due to significant unforeseen challenges associated with global enrollment of participants with genetically-defined, newly diagnosed, AML who are candidates for intensive induction therapy and other challenges associated with post-COVID impacts.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID